SOME €19 billion of Irish pharmaceutical exports may be impacted by the expiration of patents on a number of blockbuster medicines produced here.

ELAN reiterated yesterday that a substantial opportunity exists, on a commercial basis, for its planned series of treatments for Alzheimer’s disease — all of which are currently at various testing stages.

WYETH said second-quarter profit fell 4.3%, a smaller decline than analysts expected.